Anavex Life Sciences Corporation (AVXL) Options

CRDL’s commitment to addressing unmet medical needs makes its stock a compelling growth opportunity.

You just answered your own question.

Good that makes sense for another few weeks...

I hadn't heard that you suffered from mitochondria dysfunction before 

So you are selling every time someone here post a realistic analysis, one of those you refer to as bashing. Maybe if you feel sure you got your investment thesis right, you should not let yourself be persuaded by message board posts to sell $AVXL.

All I care about for the present is the EMA application. And it is unlikely to ever happen...

Today is day 3.  Hat already happened. The conference started on 11/19

Good to know that Klamer is at least working 1 day in year to earn his salary and benefit. Clown CEO works 4 days in a year and rest of the employees are on perpetual vacation.

looking great loongs.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

For all we know because an unnamed KOL whispered in Missling's ear that OLE data can take the place of a confirmatory RCT.

It is a bit more complicated that what "Gemini" told you.

Flow chart for determining filing status.

Source of your info?

Yup I'm still here making money on every irrational $AVXL price spike, while hoping too one day I will make even more on A2-73 being approved and Anavex helping patients and families.

Would be good to see some action coming from it...

I don't necessarily disagree that Missling is not the best CEO. My view is that the data will speak for itself and he has people who know how to proceed accordingly. At this point I care about the AD application and, secondly, the schizo results. 

I agree slowness is an important issue but in my opinion the other, more important issue, is whether Missling is competent to execute effectively on behalf of shareholders. Based on his track record, I do think there is reason to be deeply concerned about his competency.

All I care about for the present is the EMA application. 

So inexcusable you bought shares on Monday? LMAO

What is inexcusable is why you refuse to answer these two very simple questions:

Which drug is safer to you, mabs or our small molecule?

If both were approved, which one would you treat YOUR FAMILY member with at early stages of AD?

You too. Bash and buy. That's what helps institution gain stronger share holdings. Buy signal.

There is a P3 trial that is largely paid for by others all queued up and ready to go in Australia...why hasn't Anavex pulled the trigger on it?

The truth always hurts. You are Exhibit A for today. What investor2014 said is absolutely true. The facts, evidenced by the public record, are indisputable. Year in and year out, Missling publishes “near term” catalysts that do not come to pass.

I’ve come to see Missling’s list of “near term” catalysts as aspirational and nothing more. I’m certainly not excusing his behavior, because his behavior is immensely damaging to credibility and to shareholder value, but I think he knows perfectly well that most if not all of the catalysts are unlikely to happen in the “near term.”

One can argue that Blarcamesine’s safety and efficacy have been proven beyond a doubt. I’m not so sure but whatever anybody other than regulators thinks doesn’t matter. Ultimately it is up to regulators to make that determination. But there can be no argument that Missling’s behavior has seriously damaged Anavex’s and his own credibility and has had negative consequences for shareholders.

Yet, you are still here. Working hard this morning. Buy signal.

Missling is a bit of a promoter, and loves a trend or buzzword. And his clinical program design and management skills are relatively poor. But the company has staffed up, and 2-73 appears to be therapeutic. It's good to see.

Slowness? It is the complete absence of any concrete progress on any of the 'catalysts' that Georgejjl keeps reminding us of that is the issue.

Had Missling been slow on only a few of them fine, but the complete lack of execution on any self declared catalysts over the last few years is inexcusable.

That's not my view. His slowness is annoying but it will not change the outcome. 

The microbiome study that Anavex never mentioned again despite their claim that a two-way interaction between A2-73 and the microbiome had been found through their analysis. Super exciting to learn more about if true, but one can only assume that was another Mislling fib.

Don't remember that, boi. I'll take your word for it. 

Hey good Dr. Missling, please hear our request.

Missling loves you - a good disciple explaining away whatever he does or doesn't do is fantastic.

Yes - verified.

Love it !!!! I am dealing with mitochondrial dysfunction.

In 2004 I was given a flouroquinolone antibiotic as "treatment" for a fungal infection - Coccidioidmycosis or "Valley Fever".

The only thing it did was cripple my mitochondria.

After years of treatment I finally began to feel "normal".

Then during COVID one of the doctors I fired ordered two MRI's with gadolinium contrast without looking at my medical record and noting that my primary physician had confirmed the flouroquinolone toxicity and ordered no gadolinium. When I discovered that it had been given to me I got very angry, I screamed and yelled at those doctors and they laughed at me.

Well, it caused additional mitochondrial damage. Now I am dying and have serious memory issues. I am scheduled to begin chelation therapy which is the only way to detoxivy my brain.

This occured at UC Health, a govt supported hospital.

I was advised to contact Dr. Missling and ask for a trial of one - Blarcamesine might also help. I haven't done that yet, but I will be forwarding a copy of this post to him. After chelation therapy this seems to be my only hope of returning to "normal".

Love and light to all, and especially to fellow victims of the Medical Industrial Complex.

Personal comments can be made here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175419468

Didn't someone here uncover the stat that only 35 percent of applicants manage to get their MAA submitted on schedule?

Mitochondrial biomarker science is still quite early, and of limited use currently. It's almost as challenging as microbiome studies, in terms of complexity and independent pathways. These gatherings are nice to see, and agonizing S1 is likely an relevant element in some cases, hence our participation.

So many finger pointing posts is quite troubling:

Here is a basic math projection using the sharp break from $10.45 to $7.18 (using the normal retrace levels by Fibonacci rules...not all of them but rather the common ones):

,382 a weak retrace.....$8.42
.50....a common retrace....$8.82
.618...many professional traders rely on this level....$9.20

23.6%: This is the smallest retracement level and often represents a minor pullback.  
38.2%: This is the next smallest retracement level and is often considered a significant level of support or resistance.
50%: This is not a true Fibonacci retracement level, but it is often included because it represents a halfway point between the high and low of the previous move.  
61.8%: This is the largest Fibonacci retracement level and is often considered a strong level of support or resistance.  
78.6%: This is the largest Fibonacci retracement level and is often considered a very strong level of support or resistance.
It is important to note that these are just levels of potential support or resistance, and the price of a stock may not necessarily retrace to any of these levels. However, they can be a useful tool for traders to identify potential areas where the price of a stock may pause or reverse its trend

Nope. I simply point out FUD.

Yes I can. I already did. An artificial deadline is one that has no penalty if it is crossed. Such as an EMA filing by x date. A real deadline would be a statute of limitations, for example. 

To not spend what was needed on a program is not criminal but it is close to it. You sell people on the idea that you DO believe in the program and you ARE doing what you need to do to get it to market. Then, afterwards, you say you didn't know it would work and so you didn't spend enough money? I have a real problem with that because I believed it would work and I believed what they said about setting their programs up for success. I was so embarrassed about believing them that I didn't post here for a year after the Rett failure - I thought it was a gimme, and it should have been.

Agree that we should all hope that 2-73 is approved for AD soon. But, my point is that had the programs been run properly, like nearly any life sciences company would have done, then we wouldn't have to hope. Look at Cassava with its (probably) ineffective simufilam: they are running 2 separate P3 trials in parallel with ~2,000 total patients. Had Anavex done the same - or immediately started a 2nd P3 after the 1st one ended - then hope would not be a part of this discussion and the share price of Anavex would be 3x higher right now.

Daniel Klamer is doing a 30 min presentation at the 4th Mitochondrial Dysfunction Drug Development Summit in Boston today with this title - "Uncovering Mitochondrial & Related Pathways for Parkinson’s Disease & Dementia to Discover Biomarkers".

Then just after he's in a 45 min fireside chat - "Adopting an Integrated Approach to Measuring Mitochondrial Activity for
Validating Biomarkers".

Yesterday was day 1 which he chaired - https://www.linkedin.com/feed/update/urn:li:activity:7265132981608955904/

Powerwalker, here's what I found for you on "Gemini" since many here like these AI findings:

No, a company's market cap dropping during the year does not automatically change their SEC filing status. The SEC determines a company's filing status based on their public float (the number of publicly traded shares) at the end of their fiscal year.

However, if the company's public float drops below the threshold for their current filing status, they may become subject to different filing deadlines in the following year.

William, I was thinking that once a company are in that group of large accelerated filers, it never leaves. Why should investors be watching a pogo stick, as to whether a company files in 60 days one year, 90 in the second and back to 60 in the third. The SEC, along with investors, like consistency and allowing a company to vary such filings from year-to-year is ridiculous.

But, stranger things have happened ...

Too bad that no one followed up to see that the story was false. Where is Ern today?

It looks like it could maybe possibly work better than what is currently out there...it is what it is. Only a large properly planned trials would prove what you claim.

That isn't the point. If a company gives 10 "artificial timelines" annually, andaybe delivers on one of them, they cannot be trusted toanage properly...it means they don't know how to manage projects...it is a problem.

If your wife constantly told you that she would be home from work by a certain time and was frequently an hour late without being promoted for working so hard...you may want to get a PI to find out who in the office she is "working on so hard". It has to do with trust.

Same thing every year since they changed their company from a photo print shop to a drug company.

They always lost ten items and possibly complete one withing the year that they list the catalyst.

As there is a lot talk about and use of LMMs like ChatGPT to 'help' understand e.g. the chance of approval for Anavex in AD. This talk gives an easy to follow and in depth understanding of the capabilities and limitations of this type of AI.

Many here do indeed need to think much more as an investors in a speculative stock.

Biotech is not for everyone.

A blatant pumper and Missling apologist has been in plain sight for quite some time.

Can you define "Artificial deadlines" and mention a handful of companies that successfully sell products and services grounded in setting artificial deadline?

How's that rent collection going? 🤣

When discussing "muscarinic M1" in relation to schizophrenia and PANSS, it refers to the potential therapeutic role of activating the M1 subtype of muscarinic acetylcholine receptors as a novel treatment strategy for schizophrenia, where improvements in symptoms can be measured using the Positive and Negative Syndrome Scale (PANSS), with research showing that targeting M1 receptors may lead to significant reductions in PANSS scores, indicating symptom improvement in patients with schizophrenia.

Anavex 3-71 for the treatment of schizophrenia.

Good luck and GOD bless,